Evidence-based radiation dose limitation to the vertebral bone marrow for Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Lung CancerEvidence-based radiation dose limitation to the vertebral bone marrow - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new type of radiation therapy can help cancer patients by limiting side effects and improve disease control.

Eligible Conditions
  • Lung Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Baseline to study end (up to 5 years)

6 weeks
Limited G3L Toxicity
Year 5
Change in Neutrophil to Lymphocyte ratio (NLR)
Local Recurrence (LR)
Metastasis Free Survival (MFS)
Overall Survival (OS)
Progression free Survival (PFS)

Trial Safety

Trial Design

1 Treatment Group

Radiation Dose Limitations to VMAT
1 of 1

Experimental Treatment

55 Total Participants · 1 Treatment Group

Primary Treatment: Evidence-based radiation dose limitation to the vertebral bone marrow · No Placebo Group · N/A

Radiation Dose Limitations to VMAT
Other
Experimental Group · 1 Intervention: Evidence-based radiation dose limitation to the vertebral bone marrow · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to study end (up to 5 years)

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
397 Previous Clinical Trials
73,612 Total Patients Enrolled
Neil Newman, MDPrincipal InvestigatorThe University of Texas Health Science Center - Mays Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a stage IV, M1 disease, in which definitive concurrent chemoradiotherapy to the thorax is planned.
AST/ALT ratio <2.5 times of ULN.